Scientists analyze the impact of two strategies in stopping COVID-19 pandemic
How can we best organize on-site workplace and school attendance periods and remote work to slow the circulation of Sars-CoV-2? […]
» Read moreHome »
By retrieving 329,942 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) records from the GISAID database, researchers from a software company […] A recent study in the field of fluid analysis reveals a diverse set of strategies utilized by alpha and beta […] With tens of millions of people worldwide having been infected by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causing […] Iain Chapple, University of Birmingham, England, presented the oral session "Longitudinal Serological and Vaccination Responses to SARS-COV-2 in Dental Professionals" […] Researchers in the United States have provided a high-resolution description of the viral dynamics involved in acute infection with severe […] Researchers at University of California San Diego School of Medicine and Rady Children’s Institute for Genomic Medicine have produced a […] Researchers at La Jolla Institute for Immunology (LJI) have found that T cells from people who have recovered from COVID-19 […] Since its emergence in Wuhan, China, in December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of […] The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic emerged in late 2019 in Wuhan, China, and has led to […]
Computational study identifies key areas of the SARS-CoV-2 genome prone to mutation
SARS-CoV-2 variants of concern employ different strategies of antibody escape
How SARS-CoV-2 vaccination symptoms differ from early COVID-19 symptoms
SARS-COV-2 infection leads to neutralizing and protective serological responses in over 70% of DPs
High individual-level variability in SARS-CoV-2 shedding may explain superspreading
3D assembloid shows how SARS-CoV-2 infects brain cells
Study highlights the importance of T cell cross reactivity in stopping severe COVID-19 infections
SARS-CoV-2 B.1.1.420 and B.1.617.1 immune escape variants reported in France
Single dose of J&J's Ad26.COV2.S vaccine effective against SARS-CoV-2 including in South Africa variant
